NICE says no to GSK's Tyverb and Roche's Herceptin, again
This article was originally published in Scrip
Neither GlaxoSmithKline's Tyverb (lapatinib) nor Roche's Herceptin (trastuzumab) represent value for money when used alongside aromatase inhibitors for treating postmenopausal women with metastatic hormone-receptor-positive breast cancer that overexpresses HER2, says NICE, the health technology appraisal institute for England and Wales. The institute also has doubts about whether the drugs improve overall survival compared to existing treatments, according to today's final draft guidance.
You may also be interested in...
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.
To maintain high prices and avoid access restrictions, companies marketing advanced therapies will have to show payers that their products save money elsewhere in the healthcare system.